Opens in a new tab

Insulet v EOFLOW (CFI, 15 October 2025)

Date15 October 2025
CourtCFI
DivisionMilan (IT) Central Division- Section
Type of actionApplication For Costs
Case number(s)UPC_CFI_774/2025
Registry referenceUPC_CFI_774/2025
PartiesInsulet Corporation v. EOFLOW Co., Ltd.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

In a decision of 15 October 2025, the judge-rapporteur of the Milan Central Division assessed the recoverable costs payable by EOFLOW to Insulet following the decision on the merits of 22 July 2025 (proceedings UPC_CFI_773/2025 and UPC_CFI_774/2025, patent EP 4 201 327). The interim award of EUR 200,000 stands and EOFLOW must pay a further EUR 113,773.40 within three weeks. The decision is useful for its method: item by item exclusions, then an overall proportionality reduction for the last phase of the proceedings.

Question

Which costs incurred by the successful party, beyond the interim award already made, are reasonable and proportionate under Rules 150 et seq.?

Decision

The application, filed within one month of the decision, was admissible and remained below the ceilings in the scale. Excluded were redacted invoice entries, which could not be checked (Rule 156), costs of rescheduling a hearing because of a lawyer’s unavailability, an opinion on Italian law that had no bearing on the dispute, and all enforcement costs, which postdate the decision and fall to the national courts (Article 82(3) UPCA). For costs incurred from 2 May 2025, the judge applied a 30% reduction, as the later proceedings were largely repetitive and the hearing concerned an infringement that was barely disputed. EUR 156,662 was reduced to EUR 109,663.40. The accepted total of EUR 313,773.40, less the interim award, leaves EUR 113,773.40 to pay.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 69(1) and Art. 82(3)
Rules of Procedure
Rules 150, 151, 152, 156, 157 and 221
Administrative Committee
Scale of ceilings for recoverable costs
Case law cited
Düsseldorf Local Division, UPC_CFI_16/2024, MSG Maschinenbau v EJP Maschinenbau, Munich Local Division, 19 March 2025 (UPC_CFI_696/2024), Seoul Viosys v expert, Düsseldorf Local Division (UPC_CFI_363/2023), Court of Appeal, 30 April 2025 (UPC_CoA_768/2024)

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Court fees and costs (UPC), Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_774/2025 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application For Costs
Outcome (Dhenne Avocats summary)
La provision de 200 000 euros est maintenue et EOFLOW doit verser 113 773,40 euros de plus à Insulet, après exclusion des postes invérifiables ou étrangers à l'instance et un abattement de 30 % sur la dernière phase.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025) · EOFLOW v Insulet (CFI, 28 May 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.